NextCure, Inc is a biotechnology business based in the US. NextCure shares (NXTC) are listed on the NASDAQ and all prices are listed in US Dollars. NextCure employs 90 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in NextCure
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NXTC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
NextCure stock price (NASDAQ: NXTC)Use our graph to track the performance of NXTC stocks over time.
NextCure shares at a glance
|Latest market close||$7.85|
|52-week range||$6.82 - $14.40|
|50-day moving average||$7.80|
|200-day moving average||$9.87|
|Wall St. target price||$19.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.92|
Buy NextCure shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy NextCure stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
NextCure price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-1.75%|
|3 months (2021-04-30)||-10.49%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
|Gross profit TTM||$-24,176,000|
|Return on assets TTM||-13.14%|
|Return on equity TTM||-20.58%|
|Market capitalisation||$200.4 million|
TTM: trailing 12 months
Shorting NextCure shares
There are currently 1.0 million NextCure shares held short by investors – that's known as NextCure's "short interest". This figure is 50.1% up from 687,766 last month.
There are a few different ways that this level of interest in shorting NextCure shares can be evaluated.
NextCure's "short interest ratio" (SIR)
NextCure's "short interest ratio" (SIR) is the quantity of NextCure shares currently shorted divided by the average quantity of NextCure shares traded daily (recently around 348653.37837838). NextCure's SIR currently stands at 2.96. In other words for every 100,000 NextCure shares traded daily on the market, roughly 2960 shares are currently held short.
However NextCure's short interest can also be evaluated against the total number of NextCure shares, or, against the total number of tradable NextCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NextCure's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 NextCure shares in existence, roughly 40 shares are currently held short) or 0.0591% of the tradable shares (for every 100,000 tradable NextCure shares, roughly 59 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NextCure.
Find out more about how you can short NextCure stock.
NextCure share dividends
We're not expecting NextCure to pay a dividend over the next 12 months.
NextCure share price volatility
Over the last 12 months, NextCure's shares have ranged in value from as little as $6.82 up to $14.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NextCure's is -0.514. This would suggest that NextCure's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, NextCure has bucked the trend.
NextCure, Inc. , a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University.
Stocks similar to NextCure
NextCure in the news
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Stocks That Hit 52-Week Lows On Tuesday
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Frequently asked questionsWhat percentage of NextCure is owned by insiders or institutions?
Currently 10.085% of NextCure shares are held by insiders and 52.673% by institutions. How many people work for NextCure?
Latest data suggests 90 work at NextCure. When does the fiscal year end for NextCure?
NextCure's fiscal year ends in December. Where is NextCure based?
NextCure's address is: 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 What is NextCure's ISIN number?
NextCure's international securities identification number is: US65343E1082 What is NextCure's CUSIP number?
NextCure's Committee on Uniform Securities Identification Procedures number is: 65343E108
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert